2型糖尿病病人Heath—Carter法体型研究

目的研究2型糖尿病（T2DM）病人的体型特征及并发其他代谢性疾病时的体型变化。方法采用Heath-Carter体型法，对205例（男132例，女73例）T2DM病人进行体型评定。按性别、年龄及是否并发其他疾病进行分组，计算体型相关指标，并与本地区已有的健康成年人体型进行比较。结果T2DM病人平均体型男性6．4—4．5—1．3，女性7．3—4．5—1．0，体型分布均以偏中胚层的内胚层体型为主（男性75．76％，女性84．93％）；其中单纯T2DM病人（单发组）平均体型男性5。3-4．2-1．7，女性6．4-4．4-1．2，以偏中胚层的内胚层体型为主（男59．09％，女77．08％）；T2DM并发其他代谢性疾病病人（多发组）平均体型男性7．0—4．6—1．1、女性9．0—4．6—0．6，以偏中胚层的内胚层体型占绝对优势（男84．09％，女100．00％）。T2DM病人体型存在性别差异和年龄差异（t=2．223～3．701，F=3．539～5．465，P〈0．05）。与本地区已有的健康成年人体型比较差异有显著性（t=2．04～16．23，P〈0．05）。结论T2DM病人体型以偏中胚层的内胚层体型为主，内因子值显著升高，在并发其他代谢性疾病的T2DM病人中表现更突出。

A STUDY ON SOMATOTYPE OF TYPE 2 DIABETIC PATIENTS USING HEATH-CARTER METHOD

Objective To study the somatotype characteristics of T2DM patients and changes of somatotypes when complicating other metabolic disorders. Methods Employing Heath-Carter somatotype method, an assessment of somatotype of 205 T2DM patients 032 males and 73 females） was undertaken. They were grouped according to sex and age and whether complicating other diseases. The somatotype-related indexes were calculated and compared with that local existing adult somatotype data in Shandong peninsula. Results The mean somatotype of the patients was 6.4-4.5-1.3 in male and 7.3-4.5-1.0 in female, mainly in the meso-endomorphy category （male 75.76 %, female 84.93%）, of whom with T2DM alone, the mean somatotype was 5.3-4.2- 1. 7 in male and 6.4-4.4-1.2 in female, mainly distributing in the rneso-endornorphy category （male 59.09 %, female 77.08 %） ; those with other metabolic diseases, the mean somatotype was 7.0-4.6-1.1 in male and 9.0-4.6-0.6 in female, mainly being in the mesoendornorphy category （male 84.09%, female 100.00%）. Gender and age differences of somatotype were noted in T2DM patients （t=2.223-3.701,F=3.539-5.465,P〈0.05）, the differences were significant between T2DM patients and normal people in the same area （t=2.04-16.23,P〈0.05）. Conclusion The main somatotype of T2DM patients falls in meso-endomorphy category with obviously increased endomorphic factor that manifests more prominent in those complicating other metabolic diseases.